The Supreme Court upheld NPPA's Rs 4.65 crore recovery from Sun Pharma for Roscilox overpricing (April 1996 - July 2003). The appeal was rejected owing to inconsistencies and Paragraph 13 of DPCO. Delhi HC found overlap with Oscar Laboratories. Sun Pharma, acting as dealer and distributor, lacked documentation, with direct contact as per DPCO definitions.
